Chemical: Drug
rabeprazole

last updated 09/14/2016

1. DPWG Guideline for rabeprazole and CYP2C19

Summary

There are currently no dosing recommendations for rabeprazole based on CYP2C19 genotype.

Annotation

The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for rabeprazole based on CYP2C19 genotype [Article:21412232]. They conclude that there are no recommendations at this time.

Phenotype (Genotype)Therapeutic Dose RecommendationLevel of EvidenceClinical Relevance
CYP2C19 PM (*2/*2, *2/*3, *3/*3)NonePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpointsPositive clinical effects
CYP2C19 IM (*1/*2, *1/*3, *17/*2, *17/*3)NonePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpointsClinical effect (not statistically significant difference); Kinetic effect (not statistically significant difference)
CYP2C19 UM (*17/*17)Noneno data was retrieved with the literature searchno data was retrieved with the literature search


Annotated Labels

  1. FDA Label for rabeprazole and CYP2C19
  2. HCSC Label for rabeprazole and CYP2C19



PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for rabeprazole

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA CYP2C19 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *1A N/A N/A N/A
No VIP available CA VA CYP2C19 *2 N/A N/A N/A
VIP No VIP available No VIP available CYP2C19 *2A N/A N/A N/A
No VIP available CA VA CYP2C19 *3 N/A N/A N/A
VIP No VIP available No VIP available CYP2C19 *3A N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *17 N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs1143634 NC_000002.11:g.113590390G>A, NC_000002.12:g.112832813G>A, NG_008851.1:g.8967C>T, NM_000576.2:c.315C>T, NP_000567.1:p.Phe105=, XM_006712496.1:c.81C>T, XP_006712559.1:p.Phe27=, rs11541230, rs17598550, rs3730338, rs386518185, rs57848697
G > A
SNP
F105F
No VIP available CA VA
rs16944 NC_000002.11:g.113594867A>G, NC_000002.12:g.112837290A>G, NG_008851.1:g.4490T>C, NM_000576.2:c.-598T>C, XM_006712496.1:c.-1552T>C, rs3827762
A > G
SNP
No VIP available No Clinical Annotations available VA
rs1799724 NC_000006.11:g.31542482C>T, NC_000006.12:g.31574705C>T, NG_007462.1:g.4133C>T, NG_012010.1:g.7607C>T, NM_000594.3:c.-1037C>T, NM_000595.3:c.*1012C>T, NM_001159740.2:c.*1012C>T, NT_113891.2:g.3052098C>T, NT_113891.3:g.3051992C>T, NT_167245.1:g.2828023C>T, NT_167245.2:g.2822438C>T, NT_167246.1:g.2885366C>T, NT_167246.2:g.2879746C>T, NT_167247.1:g.2922188C>T, NT_167247.2:g.2916603C>T, NT_167248.1:g.2836120C>T, NT_167248.2:g.2830524C>T, NT_167249.1:g.2873283C>T, NT_167249.2:g.2873985C>T, XM_011514614.1:c.*1012C>T, XM_011514615.1:c.*1012C>T, XM_011514616.1:c.*1012C>T, XM_011514617.1:c.*1012C>T, XM_011514618.1:c.*1012C>T, XM_011547250.1:c.*1012C>T, XM_011547653.1:c.*1012C>T, XM_011547654.1:c.*1012C>T, XM_011547883.1:c.*1012C>T, XM_011547884.1:c.*1012C>T, XM_011547885.1:c.*1012C>T, XM_011547886.1:c.*1012C>T, XM_011547887.1:c.*1012C>T, XM_011548050.1:c.*1012C>T, XM_011548051.1:c.*1012C>T, XM_011548242.1:c.*1012C>T, XM_011548243.1:c.*1012C>T, XM_011548436.1:c.*1012C>T, XM_011548437.1:c.*1012C>T, XM_011548438.1:c.*1012C>T, XM_011548439.1:c.*1012C>T, XM_011548440.1:c.*1012C>T, XR_952245.1:n.-1983G>A, rs112098114, rs114464955, rs117934520, rs36205301, rs3807038, rs4151108
C > T
SNP
No VIP available No Clinical Annotations available VA
rs1799964 NC_000006.11:g.31542308T=, NC_000006.11:g.31542308T>C, NC_000006.12:g.31574531T=, NC_000006.12:g.31574531T>C, NG_007462.1:g.3959T=, NG_007462.1:g.3959T>C, NG_012010.1:g.7433T=, NG_012010.1:g.7433T>C, NM_000594.3:c.-1211C>T, NM_000594.3:c.-1211T>C, NM_000595.3:c.*838C>T, NM_000595.3:c.*838T>C, NM_001159740.2:c.*838C>T, NM_001159740.2:c.*838T>C, NT_113891.2:g.3051924T=, NT_113891.2:g.3051924T>C, NT_113891.3:g.3051818T=, NT_113891.3:g.3051818T>C, NT_167245.1:g.2827849C=, NT_167245.1:g.2827849C>T, NT_167245.2:g.2822264C=, NT_167245.2:g.2822264C>T, NT_167246.1:g.2885192T=, NT_167246.1:g.2885192T>C, NT_167246.2:g.2879572T=, NT_167246.2:g.2879572T>C, NT_167247.1:g.2922014C=, NT_167247.1:g.2922014C>T, NT_167247.2:g.2916429C=, NT_167247.2:g.2916429C>T, NT_167248.1:g.2835946C=, NT_167248.1:g.2835946C>T, NT_167248.2:g.2830350C=, NT_167248.2:g.2830350C>T, NT_167249.1:g.2873109T=, NT_167249.1:g.2873109T>C, NT_167249.2:g.2873811T=, NT_167249.2:g.2873811T>C, XM_011514614.1:c.*838C>T, XM_011514614.1:c.*838T>C, XM_011514615.1:c.*838C>T, XM_011514615.1:c.*838T>C, XM_011514616.1:c.*838C>T, XM_011514616.1:c.*838T>C, XM_011514617.1:c.*838C>T, XM_011514617.1:c.*838T>C, XM_011514618.1:c.*838C>T, XM_011514618.1:c.*838T>C, XM_011547250.1:c.*838C>T, XM_011547250.1:c.*838T>C, XM_011547653.1:c.*838C>T, XM_011547653.1:c.*838T>C, XM_011547654.1:c.*838C>T, XM_011547654.1:c.*838T>C, XM_011547883.1:c.*838C>T, XM_011547883.1:c.*838T>C, XM_011547884.1:c.*838C>T, XM_011547884.1:c.*838T>C, XM_011547885.1:c.*838C>T, XM_011547885.1:c.*838T>C, XM_011547886.1:c.*838C>T, XM_011547886.1:c.*838T>C, XM_011547887.1:c.*838C>T, XM_011547887.1:c.*838T>C, XM_011548050.1:c.*838C>T, XM_011548050.1:c.*838T>C, XM_011548051.1:c.*838C>T, XM_011548051.1:c.*838T>C, XM_011548242.1:c.*838C>T, XM_011548242.1:c.*838T>C, XM_011548243.1:c.*838C>T, XM_011548243.1:c.*838T>C, XM_011548436.1:c.*838C>T, XM_011548436.1:c.*838T>C, XM_011548437.1:c.*838C>T, XM_011548437.1:c.*838T>C, XM_011548438.1:c.*838C>T, XM_011548438.1:c.*838T>C, XM_011548439.1:c.*838C>T, XM_011548439.1:c.*838T>C, XM_011548440.1:c.*838C>T, XM_011548440.1:c.*838T>C, XR_926695.1:n.-1833A>G, XR_926695.1:n.-1833G>A, XR_952245.1:n.-1809A>G, XR_952245.1:n.-1809G>A, XR_952708.1:n.-1868A>G, XR_952708.1:n.-1868G>A, XR_952889.1:n.-1833A>G, XR_952889.1:n.-1833G>A, XR_952970.1:n.-1868A>G, XR_952970.1:n.-1868G>A, XR_953043.1:n.-1868A>G, XR_953043.1:n.-1868G>A, XR_953113.1:n.-1833A>G, XR_953113.1:n.-1833G>A, rs115160975, rs117348084, rs17207141, rs36205303, rs56648300, rs57009373, rs7755285
T > C
SNP
VIP No Clinical Annotations available No Variant Annotations available
rs4244285 NC_000010.10:g.96541616G>A, NC_000010.11:g.94781859G>A, NG_008384.2:g.24154G>A, NM_000769.1:c.681G>A, NM_000769.2:c.681G>A, NP_000760.1:p.Pro227=, rs116940633, rs17879456, rs60361278
G > A
SNP
P227P
VIP No Clinical Annotations available No Variant Annotations available
rs4986893 NC_000010.10:g.96540410G>A, NC_000010.11:g.94780653G>A, NG_008384.2:g.22948G>A, NM_000769.2:c.636G>A, NP_000760.1:p.Trp212Ter, rs52827375, rs57081121
G > A
SNP
W212*
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • Irsogladine Maleate
  • Rebeprazole sodium
  • rabeprazole sodium
Trade Names
  • AcipHex
  • Pariet
Brand Mixture Names

PharmGKB Accession Id

PA451216

Type(s):

Drug

Description

Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.

Source: Drug Bank

Indication

For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Rabeprazole belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H +/K ^+^ATPase (hydrogen-potassium adenosine triphosphatase) at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton-pump inhibitor. Rabeprazole blocks the final step of gastric acid secretion. In gastric parietal cells, rabeprazole is protonated, accumulates, and is transformed to an active sulfenamide. When studied in vitro, rabeprazole is chemically activated at pH 1.2 with a half-life of 78 seconds.

Source: Drug Bank

Pharmacology

Rabeprazole prevents the production of acid in the stomach. It reduces symptoms and prevents injury to the esophagus or stomach in patients with gastroesophageal reflux disease (GERD) or ulcers. Rabeprazole is also useful in conditions that produce too much stomach acid such as Zollinger-Ellison syndrome. Rabeprazole may also be used with antibiotics to get rid of bacteria that are associated with some ulcers. Rabeprazole is a selective and irreversible proton pump inhibitor, suppresses gastric acid secretion by specific inhibition of the H +, K + -ATPase, which is found at the secretory surface of parietal cells. In doing so, it inhibits the final transport of hydrogen ions (via exchange with potassium ions) into the gastric lumen.

Source: Drug Bank

Food Interaction

Take without regard to meals.|Take without regard to meals. Food may slow absorption rate but extent of absorption is not affected.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic

Source: Drug Bank

Protein Binding

96.3% (bound to human plasma proteins)

Source: Drug Bank

Absorption

Absolute bioavailability is approximately 52%.

Source: Drug Bank

Half-Life

1-2 hours (in plasma)

Source: Drug Bank

Route of Elimination

Following a single 20 mg oral dose of 14C-labeled rabeprazole, approximately 90% of the drug was eliminated in the urine, primarily as thioether carboxylic acid; its glucuronide, and mercapturic acid metabolites.

Source: Drug Bank

Chemical Properties

Chemical Formula

C18H21N3O3S

Source: Drug Bank

Isomeric SMILES

CC1=C(C=CN=C1C[S@](=O)C2=NC3=CC=CC=C3N2)OCCCOC

Source: Drug Bank

COCCCOC1=C(C)C(CS(=O)C2=NC3=C(N2)C=CC=C3)=NC=C1

Source: Drug Bank

Canonical SMILES

COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3N2)=NC=C1

Source: Drug Bank

Average Molecular Weight

359.443

Source: Drug Bank

Monoisotopic Molecular Weight

359.130362243

Source: Drug Bank

SMILES

COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3N2)=NC=C1

Source: Drug Bank

InChI String

InChI=1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
ATP4A (source: Drug Bank )
ATP4B (source: Drug Bank )

Drug Interactions

Interaction Description
atazanavir - rabeprazole This gastric pH modifier decreases the levels/effects of atazanavir (source: Drug Bank )
atazanavir - rabeprazole This gastric pH modifier decreases the levels/effects of atazanavir (source: Drug Bank )
digoxin - rabeprazole Rabeprazole increases the effect of digoxin (source: Drug Bank )
digoxin - rabeprazole Rabeprazole increases the effect of digoxin (source: Drug Bank )
indinavir - rabeprazole Omeprazole decreases the absorption of indinavir (source: Drug Bank )
indinavir - rabeprazole Omeprazole decreases the absorption of indinavir (source: Drug Bank )
itraconazole - rabeprazole The proton pump inhibitor decreases the absorption of imidazole (source: Drug Bank )
itraconazole - rabeprazole The proton pump inhibitor decreases the absorption of imidazole (source: Drug Bank )
ketoconazole - rabeprazole The proton pump inhibitor decreases the absorption of imidazole (source: Drug Bank )
ketoconazole - rabeprazole The proton pump inhibitor decreases the absorption of imidazole (source: Drug Bank )
rabeprazole - atazanavir This gastric pH modifier decreases the levels/effects of atazanavir (source: Drug Bank )
rabeprazole - atazanavir This gastric pH modifier decreases the levels/effects of atazanavir (source: Drug Bank )
rabeprazole - dasatinib Possible decreased levels of dasatinib (source: Drug Bank )
rabeprazole - dasatinib Rabeprazole may decrease the serum level of dasatinib. (source: Drug Bank )
rabeprazole - digoxin Rabeprazole increases the effect of digoxin (source: Drug Bank )
rabeprazole - digoxin Rabeprazole increases the effect of digoxin (source: Drug Bank )
rabeprazole - enoxacin The agent decreases the absorption of enoxacin (source: Drug Bank )
rabeprazole - enoxacin Rabeprazole may decrease the absorption of enoxacin. (source: Drug Bank )
rabeprazole - indinavir Omeprazole decreases the absorption of indinavir (source: Drug Bank )
rabeprazole - indinavir Omeprazole decreases the absorption of indinavir (source: Drug Bank )
rabeprazole - itraconazole The proton pump inhibitor decreases the absorption of imidazole (source: Drug Bank )
rabeprazole - itraconazole The proton pump inhibitor decreases the absorption of imidazole (source: Drug Bank )
rabeprazole - ketoconazole The proton pump inhibitor decreases the absorption of imidazole (source: Drug Bank )
rabeprazole - ketoconazole The proton pump inhibitor decreases the absorption of imidazole (source: Drug Bank )

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to rabeprazole: 42

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors. Stroke; a journal of cerebral circulation. 2015. Leonard Charles E, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese. European journal of clinical pharmacology. 2014. Sugimoto Mitsushige, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs. Pharmacogenomics. 2014. Lima John J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Evaluation of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pantoprazole and rabeprazole. Pharmacogenomics. 2014. Román Manuel, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. PloS one. 2013. Tang Hui-Lin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ability of rabeprazole to prevent gastric mucosal damage from clopidogrel and low doses of aspirin depends on CYP2C19 genotype. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2012. Uotani Takahiro, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Alimentary pharmacology & therapeutics. 2012. Hunfeld N G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenetics and genomics. 2011. Scott Stuart A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. Journal of medicinal chemistry. 2011. Kido Yasuto, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics: From Bench to Byte- An Update of Guidelines. Clinical pharmacology and therapeutics. 2011. Swen J J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people. Journal of clinical pharmacy and therapeutics. 2010. Zhang L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults. Clinical therapeutics. 2010. Pan Xiaolin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics. 2010. Beaulieu Mathieu, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy. Helicobacter. 2010. Kuo Chao-Hung, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: A Prospective Randomized Study of Lansoprazole and Rabeprazole. Gut and liver. 2010. Lee Jeong Hoon, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori. British journal of clinical pharmacology. 2009. Yang Jyh-Chin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ADME pharmacogenetics: current practices and future outlook. Expert opinion on drug metabolism & toxicology. 2009. Grossman Iris. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and bioanalytical chemistry. 2008. Zanger Ulrich M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Machine learning methods and docking for predicting human pregnane X receptor activation. Chemical research in toxicology. 2008. Khandelwal Akash, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug target identification using side-effect similarity. Science (New York, N.Y.). 2008. Campillos Monica, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Endoscopic analysis of gastric ulcer after one week's treatment with omeprazole and rabeprazole in relation to CYP2C19 genotype. Digestive diseases and sciences. 2008. Ando Takashi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Proton pump inhibitors: an update of their clinical use and pharmacokinetics. European journal of clinical pharmacology. 2008. Shi Shaojun, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Helicobacter. 2008. Zhao Fujun, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Plasma concentration of rabeprazole after 8-week administration in gastroesophageal reflux disease patients and intragastric pH elevation. Journal of gastroenterology and hepatology. 2008. Yamano Hiro-o, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor. Pharmacogenomics. 2007. Furuta Takahisa, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy. Clinical pharmacology and therapeutics. 2006. Sugimoto Mitsushige, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. International journal of clinical pharmacology and therapeutics. 2006. Klotz U. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Therapeutic effects of 10 mg/day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism. Journal of gastroenterology and hepatology. 2006. Ariizumi Ken, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. The American journal of gastroenterology. 2006. Padol Sara, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans. World journal of gastroenterology : WJG. 2006. Hu Yong-Mei, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes. Clinical pharmacology and therapeutics. 2005. Sugimoto Mitsushige, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression. Alimentary pharmacology & therapeutics. 2004. Shimatani T, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clinical pharmacology and therapeutics. 2004. Sugimoto Mitsushige, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. European journal of gastroenterology & hepatology. 2003. Miki Ikuya, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43. European journal of pharmacology. 2003. Krusekopf Solveigh, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection. The American journal of gastroenterology. 2003. Take Susumu, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype. Journal of gastroenterology and hepatology. 2002. Inaba Tomoki, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Alimentary pharmacology & therapeutics. 2001. Horai Y, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2001. Dojo M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism. Journal of gastroenterology and hepatology. 2001. Miyoshi M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Alimentary pharmacology & therapeutics. 2000. Adachi K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The proton-pump inhibitors: similarities and differences. Clinical therapeutics. 2000. Horn J. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
62856-243-30
DrugBank:
DB01129
ChEBI:
8768
8769
KEGG Compound:
C07864
PubChem Compound:
5029
PubChem Substance:
10066
46506366
Drugs Product Database (DPD):
2243797
ChemSpider:
4853
Therapeutic Targets Database:
DAP000727
FDA Drug Label at DailyMed:
5d103551-978f-472a-9c62-51e6e4dea068

Clinical Trials

These are trials that mention rabeprazole and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.